{{Rsnum
|rsid=3814637
|Gene=CYP2C19
|Chromosome=10
|position=96521045
|Orientation=plus
|GMAF=0.07897
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=132
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 0.0 | 0.0
| HCB | 79.1 | 18.6 | 2.3
| JPT | 75.6 | 22.0 | 2.4
| YRI | 76.2 | 23.8 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 79.1 | 18.6 | 2.3
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=21692828
|Title=The Population Pharmacokinetics of R and S-Warfarin: Effect of Genetic and Clinical Factors
|OA=1
}}

{{PMID|17048007|OA=1
}} Association of warfarin dose with genes involved in its action and metabolism.

{{PMID|18574025|OA=1
}} The largest prospective warfarin-treated cohort supports genetic forecasting.

{{PMID Auto
|PMID=23941071
|Title=Association of genetic polymorphisms with warfarin dose requirements in Chinese patients
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}